clinical trial · NCT04464226
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer·phase3·active not recruiting·n = 402
CancerDarolutamide (Nubeqa, BAY1841788)
brief summary
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
started
Oct 20, 2020
primary completion
Jun 26, 2028
completion
Jun 26, 2028
last updated
Apr 15, 2026
official title
An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol